What predicts attrition in second step medication treatments for depression?

A STAR D Report

Diane Warden, A. John Rush, Stephen R. Wisniewski, Ira M. Lesser, Susan G. Kornstein, G. K. Balasubramani, Michael E. Thase, Sheldon H. Preskorn, Andrew A. Nierenberg, Elizabeth A. Young, Kathy Shores-Wilson, Madhukar H. Trivedi

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Attrition rates are high during treatment for major depressive disorder (MDD), and patients who drop out are less likely to reach remission. This report evaluates the incidence, timing, and predictors of attrition during second-step medication treatment. Outpatients in the multisite Sequenced Treatment Alternatives to Relieve Depression (STAR D) study receiving a medication augmentation (n=563) or medication switch (n=723) for non-psychotic MDD after an unsatisfactory outcome with citalopram were evaluated to determine attrition rates and pretreatment sociodemographic or clinical predictors of attrition. Twenty percent of participants receiving a medication augmentation and 27% receiving a medication switch dropped out before 12 wk in the second treatment step. Remission rates were lower for dropouts [7% vs. 43% (medication augmentation); 12% vs. 31% (medication switch)]. For medication augmentation, Black and other non-Caucasian races, Hispanic ethnicity, younger age, family history of drug abuse, concurrent drug abuse, sociodemographic disadvantage, less symptom improvement with initial citalopram treatment, and greater symptom severity when beginning augmentation were associated with attrition. For medication switch, Black and other non-Caucasian races, younger age, more melancholic features, and lower exit doses but more severe side-effects with citalopram treatment were associated with attrition. Minority status, younger age, and greater difficulty with the first treatment step are risk factors for attrition in the second treatment step. Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes.

Original languageEnglish (US)
Pages (from-to)459-473
Number of pages15
JournalInternational Journal of Neuropsychopharmacology
Volume12
Issue number4
DOIs
StatePublished - May 2009

Fingerprint

Depression
Citalopram
Major Depressive Disorder
Therapeutics
Substance-Related Disorders
Hispanic Americans
Outpatients
Incidence

Keywords

  • Adherence
  • Antidepressants
  • Attrition
  • Depression
  • Predictors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

What predicts attrition in second step medication treatments for depression? A STAR D Report. / Warden, Diane; Rush, A. John; Wisniewski, Stephen R.; Lesser, Ira M.; Kornstein, Susan G.; Balasubramani, G. K.; Thase, Michael E.; Preskorn, Sheldon H.; Nierenberg, Andrew A.; Young, Elizabeth A.; Shores-Wilson, Kathy; Trivedi, Madhukar H.

In: International Journal of Neuropsychopharmacology, Vol. 12, No. 4, 05.2009, p. 459-473.

Research output: Contribution to journalArticle

Warden, D, Rush, AJ, Wisniewski, SR, Lesser, IM, Kornstein, SG, Balasubramani, GK, Thase, ME, Preskorn, SH, Nierenberg, AA, Young, EA, Shores-Wilson, K & Trivedi, MH 2009, 'What predicts attrition in second step medication treatments for depression? A STAR D Report', International Journal of Neuropsychopharmacology, vol. 12, no. 4, pp. 459-473. https://doi.org/10.1017/S1461145708009073
Warden, Diane ; Rush, A. John ; Wisniewski, Stephen R. ; Lesser, Ira M. ; Kornstein, Susan G. ; Balasubramani, G. K. ; Thase, Michael E. ; Preskorn, Sheldon H. ; Nierenberg, Andrew A. ; Young, Elizabeth A. ; Shores-Wilson, Kathy ; Trivedi, Madhukar H. / What predicts attrition in second step medication treatments for depression? A STAR D Report. In: International Journal of Neuropsychopharmacology. 2009 ; Vol. 12, No. 4. pp. 459-473.
@article{e0b32f9ae7574aa5afbf5b87b0075224,
title = "What predicts attrition in second step medication treatments for depression?: A STAR D Report",
abstract = "Attrition rates are high during treatment for major depressive disorder (MDD), and patients who drop out are less likely to reach remission. This report evaluates the incidence, timing, and predictors of attrition during second-step medication treatment. Outpatients in the multisite Sequenced Treatment Alternatives to Relieve Depression (STAR D) study receiving a medication augmentation (n=563) or medication switch (n=723) for non-psychotic MDD after an unsatisfactory outcome with citalopram were evaluated to determine attrition rates and pretreatment sociodemographic or clinical predictors of attrition. Twenty percent of participants receiving a medication augmentation and 27{\%} receiving a medication switch dropped out before 12 wk in the second treatment step. Remission rates were lower for dropouts [7{\%} vs. 43{\%} (medication augmentation); 12{\%} vs. 31{\%} (medication switch)]. For medication augmentation, Black and other non-Caucasian races, Hispanic ethnicity, younger age, family history of drug abuse, concurrent drug abuse, sociodemographic disadvantage, less symptom improvement with initial citalopram treatment, and greater symptom severity when beginning augmentation were associated with attrition. For medication switch, Black and other non-Caucasian races, younger age, more melancholic features, and lower exit doses but more severe side-effects with citalopram treatment were associated with attrition. Minority status, younger age, and greater difficulty with the first treatment step are risk factors for attrition in the second treatment step. Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes.",
keywords = "Adherence, Antidepressants, Attrition, Depression, Predictors",
author = "Diane Warden and Rush, {A. John} and Wisniewski, {Stephen R.} and Lesser, {Ira M.} and Kornstein, {Susan G.} and Balasubramani, {G. K.} and Thase, {Michael E.} and Preskorn, {Sheldon H.} and Nierenberg, {Andrew A.} and Young, {Elizabeth A.} and Kathy Shores-Wilson and Trivedi, {Madhukar H.}",
year = "2009",
month = "5",
doi = "10.1017/S1461145708009073",
language = "English (US)",
volume = "12",
pages = "459--473",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "4",

}

TY - JOUR

T1 - What predicts attrition in second step medication treatments for depression?

T2 - A STAR D Report

AU - Warden, Diane

AU - Rush, A. John

AU - Wisniewski, Stephen R.

AU - Lesser, Ira M.

AU - Kornstein, Susan G.

AU - Balasubramani, G. K.

AU - Thase, Michael E.

AU - Preskorn, Sheldon H.

AU - Nierenberg, Andrew A.

AU - Young, Elizabeth A.

AU - Shores-Wilson, Kathy

AU - Trivedi, Madhukar H.

PY - 2009/5

Y1 - 2009/5

N2 - Attrition rates are high during treatment for major depressive disorder (MDD), and patients who drop out are less likely to reach remission. This report evaluates the incidence, timing, and predictors of attrition during second-step medication treatment. Outpatients in the multisite Sequenced Treatment Alternatives to Relieve Depression (STAR D) study receiving a medication augmentation (n=563) or medication switch (n=723) for non-psychotic MDD after an unsatisfactory outcome with citalopram were evaluated to determine attrition rates and pretreatment sociodemographic or clinical predictors of attrition. Twenty percent of participants receiving a medication augmentation and 27% receiving a medication switch dropped out before 12 wk in the second treatment step. Remission rates were lower for dropouts [7% vs. 43% (medication augmentation); 12% vs. 31% (medication switch)]. For medication augmentation, Black and other non-Caucasian races, Hispanic ethnicity, younger age, family history of drug abuse, concurrent drug abuse, sociodemographic disadvantage, less symptom improvement with initial citalopram treatment, and greater symptom severity when beginning augmentation were associated with attrition. For medication switch, Black and other non-Caucasian races, younger age, more melancholic features, and lower exit doses but more severe side-effects with citalopram treatment were associated with attrition. Minority status, younger age, and greater difficulty with the first treatment step are risk factors for attrition in the second treatment step. Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes.

AB - Attrition rates are high during treatment for major depressive disorder (MDD), and patients who drop out are less likely to reach remission. This report evaluates the incidence, timing, and predictors of attrition during second-step medication treatment. Outpatients in the multisite Sequenced Treatment Alternatives to Relieve Depression (STAR D) study receiving a medication augmentation (n=563) or medication switch (n=723) for non-psychotic MDD after an unsatisfactory outcome with citalopram were evaluated to determine attrition rates and pretreatment sociodemographic or clinical predictors of attrition. Twenty percent of participants receiving a medication augmentation and 27% receiving a medication switch dropped out before 12 wk in the second treatment step. Remission rates were lower for dropouts [7% vs. 43% (medication augmentation); 12% vs. 31% (medication switch)]. For medication augmentation, Black and other non-Caucasian races, Hispanic ethnicity, younger age, family history of drug abuse, concurrent drug abuse, sociodemographic disadvantage, less symptom improvement with initial citalopram treatment, and greater symptom severity when beginning augmentation were associated with attrition. For medication switch, Black and other non-Caucasian races, younger age, more melancholic features, and lower exit doses but more severe side-effects with citalopram treatment were associated with attrition. Minority status, younger age, and greater difficulty with the first treatment step are risk factors for attrition in the second treatment step. Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes.

KW - Adherence

KW - Antidepressants

KW - Attrition

KW - Depression

KW - Predictors

UR - http://www.scopus.com/inward/record.url?scp=67649231052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649231052&partnerID=8YFLogxK

U2 - 10.1017/S1461145708009073

DO - 10.1017/S1461145708009073

M3 - Article

VL - 12

SP - 459

EP - 473

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 4

ER -